MX2021000881A - Compuestos de piridin-2-ona utiles como antagonistas de smarca2. - Google Patents
Compuestos de piridin-2-ona utiles como antagonistas de smarca2.Info
- Publication number
- MX2021000881A MX2021000881A MX2021000881A MX2021000881A MX2021000881A MX 2021000881 A MX2021000881 A MX 2021000881A MX 2021000881 A MX2021000881 A MX 2021000881A MX 2021000881 A MX2021000881 A MX 2021000881A MX 2021000881 A MX2021000881 A MX 2021000881A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- smarca2
- methods
- compounds
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere generalmente a compuestos de piridin-2-ona y a métodos para usarlos en el tratamiento de un trastorno, tal como el cáncer o un trastorno asociado a SMARCA2, incluyendo como antagonistas (por ejemplo, inhibidores) de SMARCA2. La presente invención proporciona modalidades de tratamiento, por ejemplo, estrategias, métodos de tratamiento, métodos de estratificación de pacientes, compuestos, combinaciones y composiciones que son útiles para el tratamiento de trastornos, por ejemplo, trastornos proliferativos, tales como ciertos cánceres. Algunos aspectos de esta invención proporcionan modalidades de tratamiento, métodos, estrategias, compuestos, composiciones, combinaciones y formas de dosificación para el tratamiento de trastornos proliferativos celulares, por ejemplo, cánceres con actividad o función disminuida, o pérdida de función, de SMARCA4 con un antagonista de SMARCA2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862702481P | 2018-07-24 | 2018-07-24 | |
US201962815208P | 2019-03-07 | 2019-03-07 | |
PCT/US2019/043274 WO2020023657A1 (en) | 2018-07-24 | 2019-07-24 | Pyridin-2-one compounds useful as smarca2 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000881A true MX2021000881A (es) | 2021-06-08 |
Family
ID=67539641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000881A MX2021000881A (es) | 2018-07-24 | 2019-07-24 | Compuestos de piridin-2-ona utiles como antagonistas de smarca2. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220356174A1 (es) |
EP (1) | EP3826999A1 (es) |
JP (1) | JP2021532181A (es) |
KR (1) | KR20210038911A (es) |
CN (1) | CN112739690A (es) |
AU (1) | AU2019309373A1 (es) |
BR (1) | BR112021001263A2 (es) |
CA (1) | CA3106671A1 (es) |
CL (1) | CL2021000178A1 (es) |
CO (1) | CO2021002024A2 (es) |
IL (1) | IL280182A (es) |
MA (1) | MA53377A (es) |
MX (1) | MX2021000881A (es) |
PH (1) | PH12021550119A1 (es) |
SG (1) | SG11202100158WA (es) |
WO (1) | WO2020023657A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
WO2018081167A1 (en) | 2016-10-24 | 2018-05-03 | Yumanity Therapeutics | Compounds and uses thereof |
CN110366418A (zh) * | 2017-02-28 | 2019-10-22 | 埃皮兹姆公司 | 抑制smarca2用于治疗癌症 |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
CR20200544A (es) | 2018-05-14 | 2021-02-11 | Gilead Sciences Inc | Inhibidores de mcl-1 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
KR20230039657A (ko) * | 2020-06-18 | 2023-03-21 | 에피자임, 인코포레이티드 | 암의 치료를 위한 smarca4 억제 |
WO2022224924A1 (ja) * | 2021-04-23 | 2022-10-27 | 日本曹達株式会社 | 含窒素ヘテロアリール化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤 |
CN114057630B (zh) * | 2021-12-23 | 2023-06-02 | 郑州大学 | 吡非尼酮衍生物及其合成方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US20090136517A1 (en) * | 2007-11-28 | 2009-05-28 | Garton Andrew J | Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit |
CN101970424B (zh) * | 2008-01-22 | 2013-06-12 | 弗奈利斯(R&D)有限公司 | 具有检测点激酶1抑制活性的吲哚基吡啶酮衍生物 |
CN102098917B (zh) * | 2008-06-19 | 2016-03-16 | 艾科睿控股公司 | 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物 |
GB0912499D0 (en) * | 2009-07-18 | 2009-08-26 | Vernalis R&D Ltd | Indopyl-pyridone derivatives |
WO2016077375A1 (en) * | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
-
2019
- 2019-07-24 MX MX2021000881A patent/MX2021000881A/es unknown
- 2019-07-24 MA MA053377A patent/MA53377A/fr unknown
- 2019-07-24 US US17/262,395 patent/US20220356174A1/en active Pending
- 2019-07-24 WO PCT/US2019/043274 patent/WO2020023657A1/en unknown
- 2019-07-24 SG SG11202100158WA patent/SG11202100158WA/en unknown
- 2019-07-24 CN CN201980062462.7A patent/CN112739690A/zh active Pending
- 2019-07-24 CA CA3106671A patent/CA3106671A1/en active Pending
- 2019-07-24 EP EP19749545.0A patent/EP3826999A1/en active Pending
- 2019-07-24 KR KR1020217005491A patent/KR20210038911A/ko unknown
- 2019-07-24 JP JP2021527010A patent/JP2021532181A/ja active Pending
- 2019-07-24 BR BR112021001263-0A patent/BR112021001263A2/pt unknown
- 2019-07-24 AU AU2019309373A patent/AU2019309373A1/en active Pending
-
2021
- 2021-01-14 IL IL280182A patent/IL280182A/en unknown
- 2021-01-15 PH PH12021550119A patent/PH12021550119A1/en unknown
- 2021-01-22 CL CL2021000178A patent/CL2021000178A1/es unknown
- 2021-02-19 CO CONC2021/0002024A patent/CO2021002024A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20220356174A1 (en) | 2022-11-10 |
WO2020023657A1 (en) | 2020-01-30 |
CA3106671A1 (en) | 2020-01-30 |
AU2019309373A1 (en) | 2021-02-11 |
JP2021532181A (ja) | 2021-11-25 |
IL280182A (en) | 2021-03-01 |
KR20210038911A (ko) | 2021-04-08 |
CN112739690A (zh) | 2021-04-30 |
CO2021002024A2 (es) | 2021-05-20 |
EP3826999A1 (en) | 2021-06-02 |
BR112021001263A2 (pt) | 2021-04-27 |
SG11202100158WA (en) | 2021-02-25 |
PH12021550119A1 (en) | 2021-10-04 |
CL2021000178A1 (es) | 2021-07-09 |
MA53377A (fr) | 2021-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550119A1 (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
MX2019010149A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
MX2022012780A (es) | Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados. | |
MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
MX2018012132A (es) | Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
MX2017005553A (es) | Terapia de combinacion para cancer. | |
PH12015502575B1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
NZ707495A (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
MX2021007651A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2016003861A (es) | Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab. | |
MX368149B (es) | Derivados de imidazo [4, 5-c] piridina y pirrolo [2,3-c] piridina como inhibidores ssao. | |
MX2021009117A (es) | Pirazolopiridinas y triazolopiridinas como inhibidores receptores de adenosina a2a / a2b. | |
JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
PH12021551446A1 (en) | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |